Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

NCT02661464 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

677

Enrollment

INDUSTRY

Sponsor class

Stopped Due to the pandemic with only one participant in follow up, as the impact on the safety was determined to be negligible, the study was terminated early.

Conditions

Hemorrhagic Fever, Ebola

Interventions

BIOLOGICAL: Ad26.ZEBOV
BIOLOGICAL: MVA-BN-Filo

Sponsor

Janssen Vaccines & Prevention B.V.

Collaborators

[object Object]